Nytricx, Inc.

Nytricx, Inc., a self-certified small disadvantaged business and woman-owned small business headquartered in Athens, Georgia, develops nitric oxide-releasing polymer surface coatings for advanced medical devices as a prime recipient of federal research contracts and grants. The vendor operates exclusively as a prime (100% of recent awards) with no subcontractor activity, focusing on R&D-stage medical device innovation in vascular, wound care, and urological applications.

Nytricx's federal work centers on the National Institutes of Health and the Department of Health and Human Services. Three awards from the National Heart, Lung, and Blood Institute (NHLBI) fund development of nitric oxide-releasing intravascular catheters, prosthetic vascular grafts, and extracorporeal membrane oxygenation (ECMO) circuits designed to prevent infection and thrombosis. The National Institute of Diabetes and Digestive and Kidney Diseases awarded a grant for nitric oxide-releasing ultra-slippery antibacterial urological catheter surfaces. The Defense Health Agency funded development of a nitric oxide-driven antimicrobial dressing combined with a rapid blood clotting agent for traumatic injury treatment. Most recently, the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $745,973 firm-fixed-price contract in September 2024 (ultimate completion June 2026) for research and development of an ECMO circuit with nitric oxide-releasing surface coatings. In August 2026, NHLBI awarded $314,337 under the Cardiovascular Diseases Research program (CFDA 93.837) for a Small Business Innovation Research Phase I project on nitric oxide-releasing intravascular catheters with solid slippery surfaces (period of performance through July 2027).

Customer concentration is heavily HHS-NIH weighted, with NHLBI holding three awards and additional awards distributed across NIDDK, ASPR, and the Defense Health Agency. All six prime awards are in the biomedical device research and development category; the vendor competes full-and-open without set-asides. One award (the ASPR contract) reaches ultimate completion within the next twenty-four months, representing potential recompete exposure. The SCI dataset shows no reportable invoiced revenue in FY2024 and FY2025, consistent with the vendor's position as an R&D-stage biotech firm where grants and development contracts may not meet SCI's $150,000 invoicing threshold or may carry extended performance periods that have not yet generated billable hours in the reporting window.